Bupivacaine

CHEMBL1098 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
288.4 g/mol
LogP
3.4
Phase
4

A long-acting local anesthetic used to produce regional anesthesia or analgesia by blocking nerve conduction. It is widely used for epidural anesthesia during labor and surgery, and for peripheral nerve blocks. Bupivacaine is cardiotoxic in overdose, requiring careful dosing and monitoring during administration.

Masse moléculaire

288,4000 g/mol

LogP

3,40

TPSA

32,30 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C

InChI

InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)

Molecular Formula

C18H28N2O

HBD / HBA

1 / 2

Liaisons Rotatives

5

Atomes Lourds

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A long-acting local anesthetic used to produce regional anesthesia or analgesia by blocking nerve conduction. It is widely used for epidural anesthesia during labor and surgery, and for peripheral nerve blocks. Bupivacaine is cardiotoxic in overdose, requiring careful dosing and monitoring during administration.

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

Yes, Bupivacaine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1098. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2474. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.